AIM Immunotech vs Lyell Immunopharma
AIM Immunotech is the larger business, with $88,000 of revenue in fiscal 2025 against $36,000 for Lyell Immunopharma (2.4 times as much). Lyell Immunopharma grew faster (-41.0% against -48.2%). AIM Immunotech kept more of each dollar of sales as profit: a net margin of -15861.4% against -762355.6%.
| Latest fiscal year | AIM ImmunotechAIM, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $88,000 | $36,000 |
| Revenue growth | -48.2% | -41.0% |
| Net income | −$14.0m | −$274m |
| Operating margin | -13254.5% | -748344.4% |
| Net margin | -15861.4% | -762355.6% |
| Return on equity | — | -87.0% |
| Free cash flow | −$11.0m | −$151m |
| Cash | $3.0m | $60.2m |
| Total debt | $8.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 161 |
| Market value | $4.7m | $252m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 6 buys, 0 sales | 2 buys, 29 sales |